Stent thrombosis (ST) is a rare but severe complication of coronary procedures with high
mortality, high relapse rate and a very complex pathophysiology. An individual's …

In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have
shown excellent clinical results. However, even the latest-generation drug-eluting stent has …

Background No medium-term data are available on the random comparison between
everolimus-eluting bioresorbable vascular scaffolds and everolimus-eluting metallic stents …

Background Bioresorbable vascular scaffolds were developed to overcome the
shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI). We …

Background: Recent evidence suggests that bioresorbable vascular scaffolds (BVS) are
associated with an excess of thrombotic complications compared with metallic everolimus …

The introduction of bioresorbable vascular scaffolds (BVS) for clinical use has raised a
number of questions on whether current dual-antiplatelet therapy (DAPT) recommendations …

The introduction in clinical practice of coronary stents has set a milestone in the history of
interventional cardiology. Developed to overcome the limitation of plain old balloon …

Percutaneous coronary interventions with stent-based restorations of vessel patency have
become the gold standard in the treatment of acute coronary states. Bioresorbable vascular …

Polymeric bioresorbable scaffolds (BRS), at their early stages of invention, were considered
as a promising revolution in interventional cardiology. However, they failed dramatically …

Objectives: The authors sought to identify and verify independent correlates of device
thrombosis from an analysis of multicenter trials and registries. Background: Recent …